10-QPeriod: Q3 FY2005

ABBOTT LABORATORIES Quarterly Report for Q3 Ended Sep 30, 2005

Filed November 2, 2005For Securities:ABT

Summary

Abbott Laboratories reported strong sales growth in the third quarter and first nine months of 2005, with consolidated net sales increasing by 15.0% and 16.1% respectively, compared to the prior year periods. This growth was driven by solid performance across its key segments, including Pharmaceuticals, Diagnostics, Ross Products, and International. The company's operating earnings saw a decrease in the third quarter, primarily due to significant restructuring charges and increased selling, general, and administrative expenses. However, earnings from continuing operations for the nine-month period showed an increase, reflecting the overall sales momentum and disciplined cost management in prior periods. Financially, Abbott maintained a strong cash flow from operations, exceeding capital expenditures and dividends. The company's balance sheet remained robust with substantial current assets and managed long-term debt levels. Notably, Abbott repurchased a significant amount of its common stock during the period. Investors should note the impact of the Hospira spin-off on prior year comparative results and the ongoing restructuring efforts which are expected to continue into 2007, potentially impacting short-term profitability but aimed at long-term operational efficiency.

Key Highlights

  • 1Consolidated net sales increased by 15.0% to $5.38 billion for the third quarter and 16.1% to $16.29 billion for the first nine months of 2005.
  • 2Earnings from continuing operations for the nine months ended September 30, 2005, increased to $2.396 billion from $2.201 billion in the prior year.
  • 3Operating earnings for the third quarter decreased to $830.7 million from $1.023 billion in Q3 2004, impacted by increased operating costs and restructuring charges.
  • 4The company repurchased approximately 17.4 million shares of its common stock for approximately $802 million during the first nine months of 2005.
  • 5Significant restructuring charges of $229 million were recorded in 2005 related to global manufacturing and international commercial operations realignment.
  • 6Sales in the Pharmaceutical segment grew by 14.2% to $1.917 billion in Q3 2005, driven by increased sales of Mobic and Humira.
  • 7The company expects to record approximately $220 million in additional income tax expense in the fourth quarter of 2005 related to the planned remittance of $3.7 billion in foreign earnings.

Frequently Asked Questions

Abbott's sales growth is driven by strong performance across its key business segments: Pharmaceutical Products, Diagnostic Products, Ross Products, and International. Unit growth and the positive impact of a weaker U.S. dollar also contributed significantly to the increase in net sales.

The decrease in operating earnings for the third quarter of 2005 is primarily due to increased operating costs, including higher cost of products sold, research and development, and selling, general, and administrative expenses. Additionally, significant restructuring charges of $229 million related to global manufacturing and international commercial operations realignment negatively impacted the quarter's results.

The spin-off of Hospira, Inc. on April 30, 2004, resulted in the income and cash flows of Hospira being presented as discontinued operations for the prior year periods. This means that year-over-year comparisons for periods after the spin-off will not include Hospira's results, impacting the comparability of certain line items.

Abbott is undergoing a realignment of its global manufacturing and selected international commercial operations, which is expected to continue into 2007. The company has incurred significant charges related to these restructurings and expects to incur up to an additional $190 million in future periods, primarily for accelerated depreciation and asset dispositions. While these actions may impact short-term profitability, they are intended to improve long-term operational efficiency.